Quick Answer
Moleculin Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Moleculin Biotech, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$33.56M -28.8% |
-$26.05M +12.5% |
-$29.77M -2.6% |
-$29.02M -82.6% |
-$15.89M +8.4% |
-$17.36M -31.4% |
| Total Assets | $22.13M +30.7% |
$16.93M -55.7% |
$38.22M -33.4% |
$57.42M -31.7% |
$84.09M +189.7% |
$29.03M +15.0% |
| Cash and Equivalents | $8.88M +107.5% |
$4.28M -81.8% |
$23.55M -45.4% |
$43.15M -39.1% |
$70.90M +367.3% |
$15.17M +41.3% |
| Stockholders Equity | $15.01M +33.9% |
$11.21M -63.8% |
$30.93M -40.7% |
$52.19M -33.9% |
$78.99M +344.8% |
$17.76M +14.1% |
| R&D Expense | $15.89M -10.4% |
$17.73M -9.0% |
$19.49M +2.7% |
$18.97M +31.6% |
$14.42M +13.0% |
$12.76M +15.8% |
| Operating Income | -$25.10M +5.8% |
-$26.64M +10.1% |
-$29.63M +3.3% |
-$30.64M -33.4% |
-$22.97M -16.3% |
-$19.74M -12.7% |
| Shares Outstanding | 3.20M +2267.1% |
135,155 -93.9% |
2.23M +16.7% |
1.91M -93.3% |
28.58M +147.7% |
11.54M +51.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$25.40M | -261.6% | -42.6% |
| Total Assets | September 30, 2025 | $20.35M | -13.0% | -5.7% |
| Cash and Equivalents | September 30, 2025 | $6.70M | -28.7% | -11.3% |
| Stockholders Equity | September 30, 2025 | -$26.92M | -254.6% | -650.9% |
| R&D Expense | September 30, 2025 | $3.74M | -24.2% | +3.8% |
| Operating Income | September 30, 2025 | -$5.91M | +17.2% | -3.3% |
| Shares Outstanding | September 30, 2025 | 49.50M | +1548.9% | +63.9% |
- Moleculin Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Moleculin Biotech, Inc. reported Net Income of -$33.56 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed a decrease of -28.8% in Net Income compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported Total Assets of $22.13 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed an increase of +30.7% in Total Assets compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported Cash and Equivalents of $8.88 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed an increase of +107.5% in Cash and Equivalents compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported Stockholders Equity of $15.01 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed an increase of +33.9% in Stockholders Equity compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported R&D Expense of $15.89 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed a decrease of -10.4% in R&D Expense compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported Operating Income of -$25.10 million for fiscal year 2025.
- Moleculin Biotech, Inc. showed an increase of +5.8% in Operating Income compared to the prior fiscal year.
- Moleculin Biotech, Inc. reported Shares Outstanding of 3.20 million shares for fiscal year 2025.
- Moleculin Biotech, Inc. showed an increase of +2267.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: